IGF::OT::IGF PURPOSE: TO FULLY FUND THE PERFORMANCE UNDER TASK ORDER 2 PERIOD OF PERFORMANCE: 09/03/2015 - 09/02/2016

国家药物滥用研究所（NIDA）支持研究和开发治疗成瘾的新药。NIDA的药物开发计划包括体外评估，临床前药理学和毒理学研究，药物开发以及潜在治疗成瘾新药的临床评估。身体通常通过排泄或代谢为一种或多种活性或非活性代谢物来消除药物。代谢途径、代谢率的个体差异和酶的遗传多态性可显著影响药物的安全性和有效性。在药物开发的早期阶段了解这些代谢途径和潜在的相互作用是很重要的。人们可以使用简单、快速和低成本的体外方法来表征药物代谢，以提供毒性和有效性的预测，这可能会显著影响临床评价的设计（或启动）。

The National Institute on Drug Abuse (NIDA) supports research and development of new medications for the treatment of addiction. The medications development program of NIDA involves in vitro evaluations, preclinical pharmacology and toxicology studies, pharmaceutical development, and clinical evaluations for potential new medications for treating addiction. The body generally eliminates drugs either by excretion or by metabolism to one or more active or inactive metabolites. Metabolic pathways, individual differences in metabolic rates, and genetic polymorphism in enzymes can significantly affect safety and efficacy of the drug. It is important to understand these metabolic pathways and potential interactions at an early stage of drug development. One can characterize drug metabolism using simple, rapid, and low cost in vitro methods to provide predictions of toxicity and efficacy which may significantly affect the design (or initiation) of clinical evaluations.